Lonza Strengthens pharma, biotech and nutrition offerings

26 Feb 2019

With the new structure, Lonza is positioned to leverage its innovation programs and technology platforms to create new solutions at the food-pharma convergence and in microbial control.

Lonza has announced the internal alignment of its business structure to accelerate growth along the Healthcare Continuum and strengthen the Microbial Control business. Stefan Stoffel has been appointed to a new role on the Executive Committee as COO, Lonza Pharma Biotech & Nutrition (LPBN), responsible for operations, from 1 March.

Lonza Strengthens pharma, biotech and nutrition offerings

Incoming Group CEO Marc Funk commented: “Our new structure will nurture synergies and increase operational efficiency, which will create customer benefits. More importantly, it will enable Lonza to develop a more compelling offer across pharma, biotech and nutrition and to extend our competitive advantage in the market. Stefan is a well-regarded, long-established and strong leader in the Lonza business. His oversight of LPBN segment operations will help us to galvanize our offering and capitalize on future opportunities.”

The company will maintain two segments spanning the Healthcare Continuum – one dedicated to Lonza Specialty Ingredients (LSI) that will retain Consumer & Resources Protection and Consumer Product Ingredients and a second to Lonza Pharma Biotech & Nutrition (LPBN), combining Pharma & Biotech and Consumer Health & Nutrition.

In his newly created position, Stefan Stoffel will cover Operations, Quality, Engineering and Strategic Growth Initiatives across the LPBN segment. Stefan has been with Lonza since 1991 and has been instrumental in setting up a number of successful strategic projects, including IbexTM. Stefan will join Marc Funk (incoming CEO), Sven Abend (COO LSI) and Rodolfo Savitzky (CFO) on the Executive Committee. The commercial functions of the new LPBN segment will be driven by Marc Funk for the time being.

The alignment will enable both segments to focus on operational excellence, including an integrated global asset strategy that enables a more-cohesive supply chain and asset utilization. For the LSI segment, synergies across R&D and commercial functions will open up new market opportunities for the Microbial Control business and enable faster innovation. In the LPBN segment, translation of technology and know-how from pharma to nutrition, including regulatory and scientific expertise, will strengthen Lonza’s offering.

With this new structure, Lonza is positioned to leverage its innovation programs and technology platforms to create new solutions at the food-pharma convergence and in microbial control. Along the full spectrum, from advanced personalized medicines to functional foods, nutrition and a healthy environment, Lonza will continue to focus on driving a differentiated offering to support healthy living and to fully serve the needs of patients and consumers.

All future financial reporting will be based on the two new segments Lonza Pharma Biotech & Nutrition (LPBN) and Lonza Specialty Ingredients (LSI).

Read More

Related news

Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Onyx Scientific makes strategic investment in commercial API licence

Onyx Scientific makes strategic investment in commercial API licence

10 Jul 2019

Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.

Read more 
I Holland to share the science behind tool maintenance

I Holland to share the science behind tool maintenance

9 Jul 2019

Proper maintenance - rather than replacement - of compression tooling will improve profitability.

Read more 
Catalent extends global commercial spray drying capabilities in Europe

Catalent extends global commercial spray drying capabilities in Europe

9 Jul 2019

Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.

Read more 
Operations commence at Wasdell Group’s EU headquarters

Operations commence at Wasdell Group’s EU headquarters

8 Jul 2019

The new facility houses 11 bespoke production suites and temperature controlled high-way warehouses increases Wasdell’s capacity in clinical and commercial packaging, distribution & logistics and QP services.

Read more 
Porvair Sciences launches first Drosophila ChIP kits

Porvair Sciences launches first Drosophila ChIP kits

4 Jul 2019

Offers a single optimised Chromatrap kit with unique buffers and components for Drosophila chromatin extraction and ChIP.

Read more 
Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound

Boehringer Ingelheim expands NASH R&D pipeline with new first-in-class compound

3 Jul 2019

Yuhan Corporation to receive up to USD 870 million in upfront and success-based development and commercialization milestones, excluding royalties.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe

Fujifilm Irvine Scientific to open new cell culture media manufacturing site in Europe

2 Jul 2019

The space will support cGMP manufacturing of animal component-free, dry powder media, liquid media, and downstream bioprocessing liquids.

Read more 
Novartis bolsters ophthalmic portfolio with acquisition of Xiidra

Novartis bolsters ophthalmic portfolio with acquisition of Xiidra

1 Jul 2019

Xiidra 5% is the first and only prescription treatment approved to treat both signs and symptoms of dry eye by inhibiting inflammation caused by the disease.

Read more